Lv4
410 积分 2026-04-09 加入
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial
14天前
已完结
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
14天前
已完结
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
21天前
已完结
Iptacopan in IgA Nephropathy — Final 24-Month Data
22天前
已完结
Medication Adherence Among Patients With Kidney Disease: An Umbrella Review
23天前
已完结
Drug adherence in chronic kidney diseases and dialysis
23天前
已关闭
Designing clinical trials for rare diseases: unique challenges and opportunities
1个月前
已完结
A structure dosage form approach for solubility and dissolution rate enhancement
1个月前
已关闭
A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide
1个月前
已完结
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
1个月前
已完结
皖公网安备34019202002308
